Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 34-43

  Shah, Jatin J ^a   Jakubowiak, Andrzej J ^b   O'Connor, Owen A ^c   Orlowski, Robert Z ^a   Harvey, R Donald ^d   Smith, Mitchell R ^e   Lebovic, Daniel ^f   Diefenbach, Catherine ^g   Kelly, Kevin ^h   Hua, Zhaowei ⁱ   Berger, Allison J ⁱ   Mulligan, George ⁱ   Faessel, Hélène M ⁱ   Tirrell, Stephen ⁱ   Dezube, Bruce J ⁱ   Lonial, Sagar ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d EMORY UNIVERSITY   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEVONEDISTAT; REPLICATION LICENSING FACTOR CDT1; TRANSCRIPTION FACTOR NRF2; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPENTANE DERIVATIVE; NEDD8 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; UBIQUITIN;

ABDOMINAL DISCOMFORT; ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BACTEREMIA; BLOOD LEVEL; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LYMPHOMA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SINUS TACHYCARDIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG MONITORING; DRUG RESISTANCE; MAXIMUM TOLERATED DOSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; RETREATMENT; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS; CYCLOPENTANES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRIMIDINES; RETREATMENT; TREATMENT OUTCOME; UBIQUITINS;

EID: 84954478601     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1237     Document Type: Article

References (37)

1. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 2005; 12:1191-7.
2. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-90.
3. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2013;13:339-58.
4. O'Connor OA, Wright J, Moskowitz C, Muzzy J, Gregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
5. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010;16:719-26.
6. Herrmann J, Lerman LO, Lerman A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 2007;100:1276-91.
7. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A 2000; 97:4579-84.
8. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, et al. Nedd8 modification of cul-1 activates SCF(beta(TrCP))- dependent ubiquitination of IkappaBalpha. Mol Cell Biol 2000;20: 2326-33.
9. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37:102-11.
10. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
11. Milhollen MA, Traore T, Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515-23.
12. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800.
13. Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood 2014;123:3269-76.
14. Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res 2014;20: 1576-89.
15. McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, et al. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther 2012;11:942-51.
16. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, et al. The Nedd8-activating enzyme inhibitorMLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 2012;72:3360-71.
17. Nawrocki ST, Kelly KR, Smith PG, Keaton M, Carraway H, Sekeres MA, et al. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin Cancer Res 2015;21:439-47.
18. Smith PG, Traore T, Grossman S, Narayanan U, Carew JS, Lublinsky AR, et al. Azacitidine/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models [abstract]. Blood 2011;118:578.
19. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011;71:3042-51.
20. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
21. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
22. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
23. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
24. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res 2012;40:7416-29.
25. O'Quigley J, Pepe M, Fisher L. Continual reassessmentmethod: a practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33-48.
26. Micel LN, Tentler JJ, Smith PG, Eckhardt GS. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 2013;31:1231-8.
27. Pal A, Young MA, Donato NJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res 2014;74:4955-66.
28. Esseltine DL, Mulligan G. An historic perspective of proteasome inhibition. Semin Hematol 2012;49:196-206.
29. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010;1:708-16.
30. Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol 2015;169: 534-43.
31. Li B, Wang H, Orlowski RZ. Proteasome maturation protein (pomp) is associated with proteasome inhibitor resistance in myeloma, and its suppression enhances the activity of bortezomib and carfilzomib [abstract]. Blood 2013;122:280.
32. Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, et al. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics 2011;10: M111.
33. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitorMLN9708 against multiple myeloma cells. Clin Cancer Res 2011;17:5311-21.
34. Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleeft H, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther 2008;7: 1940-8.
35. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
36. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013;24:289-304.
37. Swords RT, Savona MR, Maris MB, Erba HP, Hua Z, Faessel H, et al. First-inclass NAE inhibitor MLN4924 in combination with azacitidine for acute myeloid leukemia (AML) patients considered unfit for conventional chemotherapy: results from the C15009 trial [abstract]. Haematologica 2014;99:223-4, (S650).